PubMed

Hypothesis to explain poor outcomes in the ALLHAT and V-HeFT trials: decreased expression of heat shock proteins.

Hooper PL.

Curr Control Trials Cardiovasc Med. 2001;2(6):251-253.PMID: 11806806 [PubMed - as supplied by publisher]Free PMC ArticleFree textRelated citations

Long-term organ protection by doxazosin and/or quinapril as antihypertensive therapy.

Gallego-Delgado J, Lazaro A, Gomez-Garre D, Osende JI, Gonzalez-Rubio ML, Herraiz M, Manzarbeitia F, Fortes J, Fernandez-Cruz A, Egido J.

J Nephrol. 2006 Sep-Oct;19(5):588-98.PMID: 17136686 [PubMed - indexed for MEDLINE]Related citations

The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis.

Einhorn PT, Davis BR, Massie BM, Cushman WC, Piller LB, Simpson LM, Levy D, Nwachuku CE, Black HR; ALLHAT Collaborative Research Group.

Am Heart J. 2007 Jan;153(1):42-53.PMID: 17174636 [PubMed - indexed for MEDLINE]Related citations

Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).

Haywood LJ, Ford CE, Crow RS, Davis BR, Massie BM, Einhorn PT, Williard A; ALLHAT Collaborative Research Group.

J Am Coll Cardiol. 2009 Nov 24;54(22):2023-31.PMID: 19926008 [PubMed - indexed for MEDLINE]Related citations

Prescribing patterns for antihypertensive drugs after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: report of experience in a health maintenance organization.

Xie F, Petitti DB, Chen W.

Am J Hypertens. 2005 Apr;18(4 Pt 1):464-9.PMID: 15831354 [PubMed - indexed for MEDLINE]Related citations

Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.

Davis BR, Piller LB, Cutler JA, Furberg C, Dunn K, Franklin S, Goff D, Leenen F, Mohiuddin S, Papademetriou V, Proschan M, Ellsworth A, Golden J, Colon P, Crow R; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group.

Circulation. 2006 May 9;113(18):2201-10. Epub 2006 May 1.PMID: 16651474 [PubMed - indexed for MEDLINE]Free ArticleRelated citations

Validation of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants Assigned to Doxazosin and Chlorthalidone.

Piller LB, Davis BR, Cutler JA, Cushman WC, Wright JT Jr, Williamson JD, Leenen FH, Einhorn PT, Randall OS, Golden JS, Haywood LJ; The ALLHAT Collaborative Research Group.

Curr Control Trials Cardiovasc Med. 2002 Nov 14;3(1):10.PMID: 12459039 [PubMed - as supplied by publisher]Free PMC ArticleFree textRelated citations

Doxazosin and congestive heart failure.

Sica DA.

Congest Heart Fail. 2002 May-Jun;8(3):178-84. Review.PMID: 12045387 [PubMed - indexed for MEDLINE]Related citations

Benefits and side effects of blood pressure lowering treatment: what was wrong with doxazosin in the ALLHAT?

Gavras I, Gavras H.

Curr Control Trials Cardiovasc Med. 2001;2(6):257-259.PMID: 11806808 [PubMed - as supplied by publisher]Free PMC ArticleFree textRelated citations

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.

JAMA. 2002 Dec 18;288(23):2981-97. Erratum in: JAMA. 2004 May 12;291(18):2196. JAMA 2003 Jan 8;289(2):178. PMID: 12479763 [PubMed - indexed for MEDLINE]Free ArticleRelated citations

Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.

Davis BR, Kostis JB, Simpson LM, Black HR, Cushman WC, Einhorn PT, Farber MA, Ford CE, Levy D, Massie BM, Nawaz S; ALLHAT Collaborative Research Group.

Circulation. 2008 Nov 25;118(22):2259-67. Epub 2008 Nov 10.PMID: 19001024 [PubMed - indexed for MEDLINE]Free PMC ArticleFree textRelated citations

Calcium channel blockers in the treatment of hypertension and prevention of cardiovascular disease: results from major clinical trials.

Black HR.

Clin Cornerstone. 2004;6(4):53-66. Review.PMID: 15850766 [PubMed - indexed for MEDLINE]Related citations

Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group.

Hypertension. 2003 Sep;42(3):239-46. Epub 2003 Aug 18.PMID: 12925554 [PubMed - indexed for MEDLINE]Free ArticleRelated citations

Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study.

Barzilay JI, Davis BR, Bettencourt J, Margolis KL, Goff DC Jr, Black H, Habib G, Ellsworth A, Force RW, Wiegmann T, Ciocon JO, Basile JN; ALLHAT Collaborative Research Group.

J Clin Hypertens (Greenwich). 2004 Mar;6(3):116-25.PMID: 15010644 [PubMed - indexed for MEDLINE]Related citations

Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Barzilay JI, Davis BR, Cutler JA, Pressel SL, Whelton PK, Basile J, Margolis KL, Ong ST, Sadler LS, Summerson J; ALLHAT Collaborative Research Group.

Arch Intern Med. 2006 Nov 13;166(20):2191-201.PMID: 17101936 [PubMed - indexed for MEDLINE]Free ArticleRelated citations

Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT Jr, Whelton PK, Barzilay J, Batuman V, Eckfeldt JH, Farber M, Henriquez M, Kopyt N, Louis GT, Saklayen M, Stanford C, Walworth C, Ward H, Wiegmann T.

Arch Intern Med. 2005 Apr 25;165(8):936-46.PMID: 15851647 [PubMed - indexed for MEDLINE]Free ArticleRelated citations

Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Black HR, Davis B, Barzilay J, Nwachuku C, Baimbridge C, Marginean H, Wright JT Jr, Basile J, Wong ND, Whelton P, Dart RA, Thadani U; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.

Diabetes Care. 2008 Feb;31(2):353-60. Epub 2007 Nov 13.PMID: 18000186 [PubMed - indexed for MEDLINE]Free ArticleRelated citations

Antihypertensive prescribing practices: impact of the antihypertensive and lipid-lowering treatment to prevent heart attack trial.

Player MS, Gill JM, Fagan HB, Mainous AG 3rd.

J Clin Hypertens (Greenwich). 2006 Dec;8(12):860-4.PMID: 17170611 [PubMed - indexed for MEDLINE]Related citations

Should ethnicity serve as the basis for clinical trial design? Importance of race/ethnicity in clinical trials: lessons from the African-American Heart Failure Trial (A-HeFT), the African-American Study of Kidney Disease and Hypertension (AASK), and the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Taylor AL, Wright JT Jr.

Circulation. 2005 Dec 6;112(23):3654-60; discussion 3666. No abstract available. PMID: 16330707 [PubMed - indexed for MEDLINE]Free ArticleRelated citations

[Clinical study of the month. Which initial antihypertensive? Results from the ALLHAT trial]

Scheen AJ, Krzesinski JM.

Rev Med Liege. 2003 Jan;58(1):47-52. French. PMID: 12647599 [PubMed - indexed for MEDLINE]Related citations